Know Cancer

or
forgot password

Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer


Phase 2
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer


OBJECTIVES:

I. Evaluate the safety of paclitaxel plus trastuzumab (Herceptin) followed by adjuvant
chemotherapy in women with node positive stage II or IIIa breast cancer with HER2
overexpression.

II. Evaluate the safety of long term trastuzumab (Herceptin) in this patient population.

OUTLINE: This is a randomized study. Patients are stratified according to radiotherapy (none
planned vs planned to breast or chest wall). Patients are randomized to one of two treatment
arms.

ARM I: Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab
(Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses
and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel
and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1
hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive
and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5
years.

ARM II: Patients receive same therapy as in Arm I, except for additional trastuzumab
(Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and
local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as
in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of
doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive
local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease
progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
annually thereafter.

PROJECTED ACCRUAL: A total of 200 patients (100 per treatment arm) will be accrued for this
study within 1 year.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed stage II or IIIa (T1-T3, N1-N2, M0) adenocarcinoma of the
breast HER2 overexpression (2-3+ by immunochemistry)

- Bilateral breast cancer allowed

- Must have had local breast cancer surgery within past 12 weeks

- Mastectomy or lumpectomy with clear surgical margins AND axillary lymph node
dissection with at least 6 nodes removed

- Hormone receptor status: Not specified

PATIENT CHARACTERISTICS:

- Age: 18 and over

- Sex: Female

- WBC at least 3,000/mm3

- Platelet count at least 100,000/mm3

- Hemoglobin at least 9 g/dL

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- Creatinine no greater than 1.5 times ULN

- LVEF at least 50%

- No history of congestive cardiomyopathy

- No congestive heart failure or myocardial infarction within the past 6 months

- No uncontrolled hypertension

- No uncontrolled arrhythmia within the past 6 months

- No other prior malignancy within the past 5 years except curatively treated basal or
squamous cell skin cancer or carcinoma in situ of the cervix

- No other serious medical illness that would limit survival to less than 2 years

- No psychiatric condition precluding study

- Not pregnant or nursing

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy for breast cancer

- No prior hormonal therapy for breast cancer

- At least one year since prior tamoxifen for chemoprevention (e.g., Breast Cancer
Prevention Trial)

- No prior radiotherapy to the breast, chest wall, or regional lymph nodes

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

George W. Sledge, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Indiana University Melvin and Bren Simon Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2012-02305

NCT ID:

NCT00003992

Start Date:

August 1999

Completion Date:

March 2009

Related Keywords:

  • Breast Cancer
  • stage II breast cancer
  • stage IIIA breast cancer
  • Breast Neoplasms

Name

Location

Albert Einstein Comprehensive Cancer CenterBronx, New York  10461
Kaplan Cancer CenterNew York, New York  10016
Mayo Clinic Cancer CenterRochester, Minnesota  55905
Stanford University Medical CenterStanford, California  94305-5408
H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida  33612
Emory University Hospital - AtlantaAtlanta, Georgia  30322
Johns Hopkins Oncology CenterBaltimore, Maryland  21287
CCOP - Ann Arbor RegionalAnn Arbor, Michigan  48106
University of Rochester Cancer CenterRochester, New York  14642
Ireland Cancer CenterCleveland, Ohio  44106-5065
University of Pennsylvania Cancer CenterPhiladelphia, Pennsylvania  19104
Robert H. Lurie Comprehensive Cancer Center, Northwestern UniversityChicago, Illinois  60611
CCOP - WichitaWichita, Kansas  67214-3882
CCOP - Missouri Valley Cancer ConsortiumOmaha, Nebraska  68131
CCOP - Colorado Cancer Research Program, Inc.Denver, Colorado  80209-5031
Veterans Affairs Medical Center - Atlanta (Decatur)Decatur, Georgia  30033
CCOP - Illinois Oncology Research AssociationPeoria, Illinois  61602
CCOP - Carle Cancer CenterUrbana, Illinois  61801
Veterans Affairs Medical Center - Indianapolis (Roudebush)Indianapolis, Indiana  46202
Beth Israel Deaconess Medical CenterBoston, Massachusetts  02215
New England Medical Center HospitalBoston, Massachusetts  02111
CCOP - KalamazooKalamazoo, Michigan  49007-3731
CCOP - Metro-MinnesotaSaint Louis Park, Minnesota  55416
CCOP - Northern New JerseyHackensack, New Jersey  07601
Vanderbilt Cancer CenterNashville, Tennessee  37232-6838
CCOP - Cedar Rapids Oncology ProjectCedar Rapids, Iowa  52403-1206
CCOP - OchsnerNew Orleans, Louisiana  70121
CCOP - Merit Care HospitalFargo, North Dakota  58122
Morristown Memorial HospitalMorristown, New Jersey  07962-1956
Medical College of WisconsinMilwaukee, Wisconsin  53226
CCOP - Central IllinoisSpringfield, Illinois  62526
Veterans Affairs Medical Center - AlbanyAlbany, New York  12208
CCOP - MainLine HealthWynnewood, Pennsylvania  19096
Veterans Affairs Medical Center - MadisonMadison, Wisconsin  53705
University of Wisconsin Comprehensive Cancer CenterMadison, Wisconsin  53792
Veterans Affairs Medical Center - Milwaukee (Zablocki)Milwaukee, Wisconsin  53295
CCOP - EvanstonEvanston, Illinois  60201
Veterans Affairs Medical Center - New YorkNew York, New York  10010
Veterans Affairs Medical Center - Chicago (Lakeside)Chicago, Illinois  60611
Trinitas Hospital - Jersey Street CampusElizabeth, New Jersey  07201
Hackensack University Medical CenterHackensack, New Jersey  07601
Veterans Affairs Medical Center - Palo AltoPalo Alto, California  94304
CCOP - Sooner StateTulsa, Oklahoma  74136
Hunterdon Regional Cancer ProgramFlemington, New Jersey  08822